Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease

With disease‐modifying treatment strategies on the horizon, stratification of individual patients at the earliest stages of Parkinson's disease (PD) is key—ideally already at clinical disease onset. Blood levels of neurofilament light chain (NfL) provide an easily accessible fluid biomarker that might allow capturing the conversion from prodromal to manifest PD.

[1]  Nick C Fox,et al.  Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study , 2019, The Lancet Neurology.

[2]  A. Durr,et al.  Neurofilaments as blood biomarkers at the preataxic and ataxic stage of spinocerebellar ataxia type 3: a cross-species analysis in humans and mice , 2019 .

[3]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[4]  Kai-Chien Yang,et al.  Blood NfL , 2019, Neurology.

[5]  Lynn Rochester,et al.  Gait analysis with wearables predicts conversion to Parkinson disease , 2019, Annals of neurology.

[6]  Paolo Eusebi,et al.  CSF and blood biomarkers for Parkinson's disease , 2019, The Lancet Neurology.

[7]  B. Bloem,et al.  Serum NFL discriminates Parkinson disease from atypical parkinsonisms , 2019, Neurology.

[8]  Yves Dauvilliers,et al.  Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study , 2019, Brain : a journal of neurology.

[9]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[10]  Wei‐Ju Lee,et al.  Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease , 2018, Scientific Reports.

[11]  A. Fallgatter,et al.  Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD) , 2018, Neurobiology of Aging.

[12]  R. Postuma,et al.  Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts , 2017, Movement disorders : official journal of the Movement Disorder Society.

[13]  K. Blennow,et al.  Blood-based NfL , 2017, Neurology.

[14]  A. Lang,et al.  Precision medicine for disease modification in Parkinson disease , 2017, Nature Reviews Neurology.

[15]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[16]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[17]  K. Blennow,et al.  Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[18]  P. Andersen,et al.  Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis , 2015, Annals of neurology.

[19]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[20]  Nick C Fox,et al.  A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[22]  Inga Liepelt-Scarfone,et al.  The Patients' Perception of Prodromal Symptoms Before the Initial Diagnosis of Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[23]  H. Zetterberg,et al.  Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. , 2010, Parkinsonism & Related Disorders.

[24]  K. Walters,et al.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.